Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer
Status
Conditions
Details and patient eligibility
About
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA(ctDNA) can help early screening of pancreatic cancer recurrence or not. And we are also planning to evaluate correlation between ctDNA with clinical outcome of pancreatic cancer.
Full description
In the formation and growth of a primary tumor, cells can released into the bloodstream. There are many researches for these circulating tumor cells(CTC) And recently circulating cell-free tumor DNA(ctDNA) released from apoptotic or necrotic tumor cells has developed. At one report which checked ctDNA level after operation of colon cancer patients, they suggested that ctDNA could show recurrence of cancer several months earlier than the conventional follow up imaging. And several reports suggested that ctDNA can invade host cell and change host cell biology, which can evoke cancer metastasis.
So in this study, the investigator will collect ctDNA of pancreatic cancer patients, benign pancreatic disease patients, and healthy population. And the investigator will evaluate whether peripheral ctDNA can help early screening of cancer recurrence. And we will study about genomic signature of ctDNA to evaluate relationship between ctDNA and clinical outcome of cancer patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Comparative group : Pancreatic cancer patients who progress endoscopic ultrasonography fine-needle aspiration (EUS-FNA) for pancreatic cancer diagnosis, pancreatic cancer patients who are in operable stage
- Control group : Benign pancreas disease patients who progress EUS-FNA for diagnosis, healthy population
Exclusion criteria
- Foreigners
- Pancreatic cancer patients who have other cancer
- Patients who impossible to consent to study by own
Trial contacts and locations
Loading...
Central trial contact
Joo Kyung Park, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal